ArticleACS medicinal chemistry letters2014
Systems biology approach to developing "systems therapeutics".
Article in ACS medicinal chemistry letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Comparative Proteomic Analysis of Dental-Origin Stem Cells: Insights into Regenerative Potential.Stem cell reviews and reports · 2025Article
- Using a "systems therapeutic for physiological renormalization" approach to vaccine development. Covid-19 as an example.Human vaccines & immunotherapeutics · 2022Article
- Neuroprotection of retinal ganglion cellsNeuronal signaling · 2022Article
- Stem cells part of the innate and adaptive immune systems as a therapeutic for Covid-19.Communicative & integrative biology · 2021Review
- The safety of a therapeutic product composed of a combination of stem cell released molecules from adipose mesenchymal stem cells and fibroblasts.Future science OA · 2020Article
- Physiological renormalization using systems therapeutics.Future science OA · 2019Article
- Transplanted stem cells survive a long time: do they make you sick?Journal of the Royal Society of Medicine · 2019Article
- Rescue of degenerating neurons and cells by stem cell released molecules: using a physiological renormalization strategy.Physiological reports · 2019Article
- Multi-dimensional computational pipeline for large-scale deep screening of compound effect assessment: an in silico case study on ageing-related compounds.NPJ systems biology and applications · 2019Article
- Amyotrophic lateral sclerosis as a protein level, non-genomic disease: Therapy with S2RM exosome released molecules.World journal of stem cells · 2017Review
- Therapeutics from Adult Stem Cells and the Hype Curve.ACS medicinal chemistry letters · 2016Article
- Systems biology approach to developing S(2)RM-based "systems therapeutics" and naturally induced pluripotent stem cells.World journal of stem cells · 2015Review
- Maturing from embryonic to adult policy on stem cell therapeutics.ACS medicinal chemistry letters · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standard drug development model uses reductionist approaches to discover small molecules targeting one pathway. Although systems biology analyzes multiple pathways, the approach is often used to develop a small molecule interacting at only one pathway in the system. Similar to that in physics where a departure from the old reductionist "Copenhagen View" of quantum physics to a new and predictive systems based, collective model has emerged yielding new breakthroughs such as the LASER, a new model is emerging in biology where systems biology is used to develop a new technology acting at multiple pathways called "systems therapeutics."
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.